Plantamajoside exerts antifibrosis effects in the liver by inhibiting hepatic stellate cell activation

Wang,Yun; Yan,Dongliang

doi:10.3892/etm.2019.7843

Plantamajoside exerts antifibrosis effects in the liver by inhibiting hepatic stellate cell activation

Authors:
- Yun Wang
- Dongliang Yan
View Affiliations

Affiliations: Department of Pharmacy, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210004, P.R. China, Department of General Surgery, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: August 2, 2019 https://doi.org/10.3892/etm.2019.7843
Pages: 2421-2428
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pathogenesis of liver fibrosis involves the activation of hepatic stellate cells (HSCs) into muscle fiber cells and fibroblasts. The aim of the current study was to investigate whether plantamajoside (PMS) exerted antifibrosis effects by affecting HSCs activation and survival during liver fibrosis, and to investigate the underlying mechanism. HSC‑T6 cells were activated by exposure to platelet‑derived growth factor BB (PDGF‑BB), and were subsequently treated with increasing concentrations of PMS (0, 20, 40, 80 and 160 µg/ml). Cell viability, apoptosis, migration and invasion were determined using the Cell Counting Kit‑8 (CCK‑8) assay, flow cytometry and the Transwell assay, respectively. Results indicated that PDGF‑BB significantly activated HSC‑T6 cells, demonstrated by increased cell proliferation, enhanced cell migration and invasion as well as increased expression of α‑smooth muscle actin (α‑SMA) and collagen type 1 α 1 (Col1α1). PMS inhibited proliferation, induced cell apoptosis and prevented cell migration and invasion in PDGF‑BB‑treated HSC‑T6 cells in what appeared to be a dose‑dependent manner. PMS appeared to dose‑dependently reduce the protein and mRNA levels of α‑SMA and Col1α1 in PDGF‑BB‑treated HSC‑T6 cells. Furthermore, the results of the present study suggested that PMS administration inhibited the protein expression of phosphorylated‑protein kinase B in what appeared to be a dose‑dependent manner. In conclusion, the data indicated that PMS exhibited an antifibrotic effect in the liver by inhibiting hepatic stellate cell activation and survival.

View Figures

View References

1	Lee UE and Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clinical Gastroenterol. 25:195–206. 2011. View Article : Google Scholar
2	Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI
3	Popov Y and Schuppan D: Targeting liver fbrosis: Strategies for development and validation of antifibrotic therapies. Hepatology. 50:1294–1306. 2009. View Article : Google Scholar : PubMed/NCBI
4	Brown-Clay JD, Shenoy DN, Timofeeva O, Kallakury BV, Nandi AK and Banerjee PP: PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget. 6:15594–15609. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zhang CY, Yuan WG, He P, Lei JH and Wang CX: Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar : PubMed/NCBI
6	Bataller R and Brenner DA: Liver fibrosis. J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
7	Schuppan D: Liver fibrosis: Common mechanisms and antifibrotic therapies. Clin Res Hepatol Gastroenterol. 39 (Suppl):S51–S59. 2015. View Article : Google Scholar : PubMed/NCBI
8	Koyama Y, Xu J, Liu X and Brenner DA: New developments on the treatment of liver fibrosis. Dig Dis. 34:589–596. 2016. View Article : Google Scholar : PubMed/NCBI
9	Samuelsen AB: The traditional uses, chemical constituents and biological activities of plantago major L. A review. J Ethnopharmacol. 71:1–21. 2000. View Article : Google Scholar : PubMed/NCBI
10	Huang DF, Tang YF, Nie SP, Wan Y, Xie MY and Xie XM: Effect of phenylethanoid glycosides and polysaccharides from the seed of Plantago asiatica L. on the maturation of murine bone marrow-derived dendritic cells. Eur J Pharmacol. 620:105–111. 2009. View Article : Google Scholar : PubMed/NCBI
11	Wu H, Zhao G, Jiang K, Chen X, Zhu Z, Qiu C, Li C and Deng G: Plantamajoside ameliorates lipopolysaccharide-induced acute lung injury via suppressing NF-κB and MAPK activation. Int Immunopharmacol. 35:315–322. 2016. View Article : Google Scholar : PubMed/NCBI
12	Pei S, Yang X, Wang H, Zhang H, Zhou B, Zhang D and Lin D: Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and −2. BMC Cancer. 15:9652015. View Article : Google Scholar : PubMed/NCBI
13	Li X, Chen D, Li M, Gao X, Shi G and Zhao H: Plantamajoside inhibits lipopolysaccharide-induced epithelial-mesenchymal transition through suppressing the NF-κB/IL-6 signaling in esophageal squamous cell carcinoma cells. Biomed Pharmacother. 102:1045–1051. 2018. View Article : Google Scholar : PubMed/NCBI
14	Ma C and Ma W: Plantamajoside inhibits lipopolysaccharide-induced MUC5AC expression and inflammation through suppressing the PI3K/Akt and NF-κB signaling pathways in human airway epithelial cells. Inflammation. 41:795–802. 2018. View Article : Google Scholar : PubMed/NCBI
15	Son WR, Nam MH, Hong CO, Kim Y and Lee KW: Plantamajoside from Plantago asiatica modulates human umbilical vein endothelial cell dysfunction by glyceraldehyde-induced AGEs via MAPK/NF-κB. BMC Complement Altern Med. 17:662017. View Article : Google Scholar : PubMed/NCBI
16	Puche JE, Saiman Y and Friedman SL: Hepatic stellate cells and liver fibrosis. Compr Physiol. 3:1473–1492. 2013. View Article : Google Scholar : PubMed/NCBI
17	Higashi T, Friedman SL and Hoshida Y: Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
18	Panebianco C, Oben JA, Vinciguerra M and Pazienza V: Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: A putative synergy between retinoic acid and PPAR-gamma signalings. Clin Exp Med. 17:269–280. 2017. View Article : Google Scholar : PubMed/NCBI
19	Lin X, Kong LN, Huang C, Ma TT, Meng XM, He Y, Wang QQ and Li J: Hesperetin derivative-7 inhibits PDGF-BB-induced hepatic stellate cell activation and proliferation by targeting Wnt/β-catenin pathway. Int Immunopharmacol. 25:311–320. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wu X, Zhi F, Lun W, Deng Q and Zhang W: Baicalin inhibits PDGF-BB-induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR-3595/ACSL4 axis. Int J Mol Med. 41:1992–2002. 2018.PubMed/NCBI
21	Yang Y, Chen XX, Li WX, Wu XQ, Huang C, Xie J, Zhao YX, Meng XM and Li J: EZH2-mediated repression of Dkk1 promotes hepatic stellate cell activation and hepaticfibrosis. J Cell Mol Med. 21:2317–2328. 2017. View Article : Google Scholar : PubMed/NCBI
22	Yang L, Zhang CZ and Zhu QJ: Kangxian ruangan keli inhibits hepatic stellate cell proliferation mediated by PDGF. World J Gastroenterol. 9:2050–2053. 2003. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Schuppan D: Structure of the extracellular matrix in normal and fibrotic liver: Collagens and glycoproteins. Semin Liver Dis. 10:1–10. 1990. View Article : Google Scholar : PubMed/NCBI
25	Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ and Sobin LH: The morphology of cirrhosis. Recommendations on defnition, nomenclature, and classifcation by a working group sponsored by the world health organization. J Clin Pathol. 31:395–414. 1978. View Article : Google Scholar : PubMed/NCBI
26	Mormone E, George J and Nieto N: Molecular pathogenesis of hepatic fbrosis and current therapeutic approaches. Chem Biol Interact. 193:225–231. 2011. View Article : Google Scholar : PubMed/NCBI
27	Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW and Tsukamoto H: Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem. 279:4820–4828. 2004. View Article : Google Scholar : PubMed/NCBI
28	Altamirano-Barrera A, Barranco-Fragoso B and Méndez-Sánchez N: Management strategies for liver fibrosis. Ann Hepatol. 16:48–56. 2017. View Article : Google Scholar
29	Gressner AM: Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: A key event in hepatic fibrogenesis. Kidney Int. 54 (Suppl):S39–S45. 1996.
30	Drescher HK, Schumacher F, Schenker T, Baues M, Lammers T, Hieronymus T, Trautwein C, Streetz KL and Kroy DC: c-Met signaling protects from nonalcoholic steatohepatitis-(NASH-) induced fibrosis in different liver cell types. Oxid Med Cell Longev 2018. 69574972018.
31	Wong L, Yamasaki G, Johnson RJ and Friedman SL: Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest. 94:1563–1569. 1994. View Article : Google Scholar : PubMed/NCBI
32	Wu CI, Hoffman JA, Shy BR, Ford EM, Fuchs E, Nguyen H and Merrill BJ: Function of Wnt/β-catenin in counteracting Tcf3 repression through the Tcf3-β-catenin interaction. Development. 139:2118–2129. 2012. View Article : Google Scholar : PubMed/NCBI
33	Fang L, Zhan S, Huang C, Cheng X, Lv X, Si H and Li J: TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via PI3K and ERK pathways. Toxicol Appl Pharmacol. 272:713–725. 2013. View Article : Google Scholar : PubMed/NCBI
34	Tao H, Huang C, Yang JJ, Ma TT, Bian EB, Zhang L, Lv XW, Jin Y and Li J: MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology. 290:327–333. 2011. View Article : Google Scholar : PubMed/NCBI
35	Woodhoo A, Iruarrizaga-Lejarreta M, Beraza N, García-Rodríguez JL, Embade N, Fernández-Ramos D, Martínez-López N, Gutiérrez-De Juan V, Arteta B, Caballeria J, et al: Human antigen R contributes to hepatic stellate cell activation and liver fibrosis. Hepatology. 56:1870–1882. 2012. View Article : Google Scholar : PubMed/NCBI
36	El-Mihi KA, Kenawy HI, El-Karef A, Elsherbiny NM and Eissa LA: Naringin attenuates thioacetamide-induced liver fibrosis in rats through modulation of the PI3K/Akt pathway. Life Sci. 187:50–57. 2017. View Article : Google Scholar : PubMed/NCBI
37	Chen Q, Chen L, Wu X, Zhang F, Jin H, Lu C, Shao J, Kong D, Wu L and Zheng S: Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway. IUBMB Life. 68:220–231. 2016. View Article : Google Scholar : PubMed/NCBI
38	Wang J, Chu ES, Chen HY, Man K, Go MY, Huang XR, Lan HY, Sung JJ and Yu J: microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget. 6:7325–7338. 2015.PubMed/NCBI